Expansion Opportunity Nemera is expanding manufacturing capacity in France with a new 7,200-square-meter facility in Ponts-et-Marais and a 5,000 sqm hall at La Verpillière, signaling increased production capacity and potential for new device programs and scale-up opportunities with large-volume and biologic therapies.

Large-Volume Biologics The launch of a fully compatible 5.5 ml prefillable glass syringe with a passive safety system for subcutaneous self-injection targets large-volume and biologic therapies, creating a conduit for partnerships around high-value, patient-friendly delivery solutions.

Diversified Delivery Nemera covers ophthalmic, nasal, inhalation, dermal/transdermal, and parenteral delivery, offering cross-category opportunities with pharma clients seeking multi-portfolio device strategies and one-stop development-to-market support.

Strategic Partnerships Recent collaborations with Therakind to advance DriDose dry powder intranasal technology and joint development programs indicate readiness to co-create next-gen nasal delivery platforms, opening doors for co-development deals and technical due diligence engagements.

Self-Administration Focus DuoSpray bi-dose nasal platform and emphasis on patient-centric, needle-free administration align with trends toward at-home therapies, enabling sales conversations around adherence-driven devices, regulatory timelines, and economics for self-administered regimens.